David Liew chats with Sophie Stocker, co-chair of the Royal College of Pathologists of Australasia Pharmacogenomics Working Group, about using pharmacogenomics to personalise drug therapy. They discuss pre-emptive, concurrent and reactive testing, and the current landscape of pharmacogenomics in Australia. Read the full article by Sophie and her co-author, Thomas Polasek, in Australian Prescriber.

Justin Coleman talks to Kate McKenzie, General Practitioner and member of one of the Antibiotic Expert Groups, in part 2 of our series on the latest updates to Therapeutic Guidelines: Antibiotic. This episode focuses on changes to guidance for primary care, including new recommendations for UTIs, infectious diarrhoea, bronchiectasis, infections of diabetes-related foot ulcers and much more.

Laura Beaton speaks with Emma Mason, lecturer in sexual and reproductive health, about the latest changes in contraceptive products in Australia. They outline key practice points for selecting appropriate contraception and managing adverse effects, as well as some useful resources to support the prescribing of contraceptives. Read the full paper by Emma and her co-author, Kirsten Black, in Australian Prescriber.

Jo Cheah chats to dermatologist Jonathan Chan about the latest therapies for psoriasis. Jonathan outlines the different treatments for mild to moderate and moderate to severe psoriasis, and when to refer patients to a non-GP specialist. They discuss the benefits and risks associated with biologic medicines for psoriasis, and considerations for patients with comorbidities. Read the full article by Jonathan in Australian Prescriber.

Dhineli Perera talks to pharmacists Amy Legg and Tony Lai about their paper on the safe and effective use of vancomycin. They discuss the evolution of vancomycin therapeutic drug monitoring, including trough concentrations, and demystify AUC monitoring. They cover current recommendations, including targets for drug efficacy and safety, and priority patient groups. Read the full article by Amy, Tony, and their co-authors, in Australian Prescriber.

Justin Coleman speaks with Alice Poulton, genetic counsellor, about noninvasive prenatal testing (NIPT) to screen for aneuploidies such as trisomy 21 (Down syndrome). Alice explains how NIPT differs from serum screening and ultrasound options, and when each option may be used. The conversation also covers advice on interpreting the NIPT results and when invasive testing may be offered. Read the full paper in Australian Prescriber.

David Liew talks to Linny Phuong, paediatric infectious diseases physician, about changes to prevention and management of respiratory syncytial virus (RSV). They discuss how RSV infections affect communities in Australia, high-risk groups to watch out for, and when to test for RSV. Linny also outlines available RSV immunisations for different populations. Read the full article by Linny and her co-author, David Foley, in Australian Prescriber.

Dhineli Perera chats with Allen Cheng, director of Infectious Diseases at Monash Health and member of the Antibiotic Expert Group, about some of the updates in the latest version of Therapeutic Guidelines: Antibiotic. Allen talks about changes to severity assessment and treatment for community-acquired pneumonia, updated antimicrobial dosing advice, a new tiered approach for managing patients with sepsis and much more.

Jo Cheah talks to Bronwyn Jenkins, consultant neurologist, about the role of calcitonin gene-related peptide (CGRP)–targeted therapies in migraine treatment. Bronwyn explains the difference between tension-type headaches and migraines, and outlines current treatment options. The conversation also covers adverse effects, patient eligibility, and other important considerations for prescribers. Read the full article in Australian Prescriber.

Justin Coleman speaks with Kate Ziser, a pharmacist at the Princess Alexandra Hospital in Brisbane, about her paper on the role of triple antithrombotic therapy in patients with atrial fibrillation following coronary stent insertion. Kate explains when triple therapy is indicated, the duration of therapy, and the step-down approach to antithrombotic therapy. Read the full article by Kate and her co-authors in Australian Prescriber.